BRIEF published on 10/15/2024 at 07:03, 1 month 6 days ago DocMorris Accelerates Prescription Medicine Growth Revenue Growth Telehealth DocMorris AG Prescription Medicine Logistics Closure
PRESS RELEASE published on 10/15/2024 at 06:58, 1 month 6 days ago DocMorris accelerates Rx growth DocMorris accelerates Rx growth with a 12.2% revenue increase in Q3, new CTO appointed, and logistics site closure in Germany. Strong growth in e-prescriptions and customer base E-prescriptions DocMorris CTO Appointment Rx Growth Logistics Site Closure
BRIEF published on 08/20/2024 at 07:03, 3 months 1 day ago DocMorris Enhances Prescription Business and Boosts New Rx Customer Investment 2024 Outlook E-prescriptions DocMorris Prescription Business TeleClinic
PRESS RELEASE published on 08/20/2024 at 06:58, 3 months 1 day ago DocMorris grows in the prescription business and invests incrementally in new Rx customers DocMorris reports growth in prescription business and increased investments in new Rx customers. Break-even reached, outlook for 2024 adjusted due to e-prescription transition Financial Results E-prescriptions New Customers DocMorris Prescription Business
BRIEF published on 07/11/2024 at 07:03, 4 months 10 days ago DocMorris Reports Significant eRx Growth in Q2 2024 Revenue Increase Market Expansion DocMorris ERx Growth
PRESS RELEASE published on 07/11/2024 at 06:58, 4 months 10 days ago DocMorris with accelerated and significant eRx growth in new customers, market share and revenue DocMorris reports accelerated eRx growth in new customers, market share, and revenue, with significant progress in eRx business and expanding customer base Revenue Market Share DocMorris ERx Growth CardLink
BRIEF published on 05/23/2024 at 07:03, 5 months 29 days ago DocMorris AG Announces Early Redemption of 2.75% Convertible Bonds Convertible Bonds Financial Announcement Early Redemption DocMorris AG Bond Conversion
PRESS RELEASE published on 05/23/2024 at 06:58, 5 months 29 days ago DocMorris AG: Early redemption of the 2.75% Convertible Bonds due 2025 DocMorris AG announces the early redemption of 2.75% Convertible Bonds due 2025 in accordance with set conditions. Bondholders should act promptly Convertible Bonds Bondholders Early Redemption Announcement DocMorris AG
BRIEF published on 05/14/2024 at 07:05, 6 months 7 days ago DocMorris AG Announces Tender Offer Results Financial Results Investor Relations Tender Offer Corporate Bonds DocMorris AG
PRESS RELEASE published on 05/14/2024 at 07:00, 6 months 7 days ago DocMorris AG: DocMorris announces results of Tender Offer DocMorris AG announces results of Tender Offer. Find more information in the press release linked. For details visit: https://ir-corporate.docmorris.com/en/investor-relations/convertible-bonds-2024 Convertible Bonds Press Release Tender Offer SIX Swiss Exchange DocMorris AG
Published on 11/21/2024 at 14:00, 20 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 20 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 20 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 13:30, 50 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 12:35, 1 hour 44 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 2 hours 5 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 22 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 35 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 35 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
